Torrent Pharmaceuticals Limited and Zydus Lifesciences Limited announced a significant licensing and supply agreement to co-market Saroglitazar Mg, a drug for treating Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) in India. As the only drug approved in the country for these liver disorders, Saroglitazar Magnesium is poised to play a crucial role in managing these conditions.

Saroglitazar Mg: An Innovative Solution for Liver Health

Under the terms of this agreement, Torrent Pharmaceuticals gains semi-exclusive rights to co-market Saroglitazar Mg under the brand name VORXAR in India. Zydus will continue marketing the drug under the brand names Lipaglyn and Bilypsa. Torrent will compensate Zydus with upfront licensing fees and milestone payments.

Expanding Access to Critical Liver Disease Treatment

Saroglitazar Mg, developed by Zydus, is the first drug approved in India for chronic liver diseases such as NASH and NAFLD. The once-daily, 4mg dose regimen of Saroglitazar Mg offers better patient compliance and convenience.

Industry Leaders Comment on the Collaboration

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, highlighted the partnership’s role in extending the reach of this critical treatment. Aman Mehta, Director of Torrent Pharmaceuticals, emphasized the drug’s significance in addressing prevalent liver diseases with limited therapeutic options.

Impact of Saroglitazar Mg on Liver Disease Treatment

Saroglitazar Mg, with its dual PPAR alpha and gamma properties, has been approved for various treatments, including NASH, NAFLD, and Type 2 Diabetes Mellitus. The collaboration is expected to benefit over 15 lac patients who have already been treated with this innovative drug.

About Torrent Pharmaceuticals and Zydus Lifesciences:

These companies are pioneering new pathways in healthcare, with a focus on providing advanced treatments for liver diseases and other health conditions in India.

  Dr. Sharvil Patel, India, NAFLD, NASH, Saroglitazar Mg, Torrent Pharmaceuticals, VORXAR, Zydus Lifesciences